Business
Collegium Provides 2026 Financial Guidance and Business Update
– Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM® Net Revenue Expected in the Range of $190 Million to $200 Million
About this update from Collegium Pharmaceutical, Inc.
[{"type":"text","content":"– Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA* Expected in the Range of $455 Million to $475 Million – STOUGHTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced its 2026 full-year financial guidance and provided a business update. “2025 was a year of record growth for Collegium and we are excited to begin 2026 with significant momentum for continued success,” said Vikram Karnani, President and Chief Executive Officer. “The outstanding performance of Jornay PM, along with sustained revenue growth across our pain portfolio, has put us in a strong financial position as we enter the year ahead. We remain dedicated to supporting patients with serious medical conditions while delivering value to our shareholders through strong commercial execution, strategic business development, and disciplined capital deployment.” “We are on track to achieve our recently increased financial guidance for 2025 and expect additional topline revenue growth in 2026 to be driven largely by increasing Jornay PM sales,” said Colleen Tupper, Chief Financial Officer. “In addition, we look forward to executing our capital deployment strategy which balances paying down debt, opportunistically repurchasing shares, and actively evaluating opportunities to expand and diversify our portfolio through business development.” Recent Business Highlights Based on continued strength across the Company’s ADHD and pain portfolios, raised full-year 2025 financial guidance in November 2025 to be in the range of $775 to $785 million for net revenue with adjusted EBITDA in the range of $460 to $470 million, with annual results expected to be reported in February 2026.In late December, announced the successful closing of a $980 million syndicated credit facility which was used in part to repay the remaining $581 million of principal representing the entire remaining balance of our previous $646 million term loan secured from funds managed by Pharmakon Advisors, LP. The new aggregate credit facility consists of a five-year $580 million senior secured term loan, $300 million delayed draw term loan, and $100 million revolving credit facility (collectively the “Credit Facility”). The reduced rate...